Year: 2022
Type: editorial
Abstract: Mature T-cell leukemias represent rare, but increasingly recognized diseases of which, compared to their B-cell counterparts, comparatively little is established on their pathogenesis, diagnosis, and treatment. These leukemic post-thymic T-cell neoplasms range from the spectrum of chronic, sometimes debilitating disorders such as T-large granular lymphocytic leukemia (T-LGLL), and related leukemias such as NK-LGLL, to more aggressive malignancies such as Tprolymphocytic leukemia (T-PLL). In this series, entitled 'Pathogenesis, Treatment, and Future Directions for Rare T-cell Leukemias' we review the current state of the science of these important T-cell neoplasms to inform on their treatment, diagnosis, and pathophysiology. LGLL. 2 Further, using an alternate approach targeting IL-15, the only currently enrolling prospective trial in the United States (NCT05141682) uses the hypomethylating agent CC-486 to treat patients with T-LGLL based on data demonstrating its efficacy in decreasing IL-15. 3 Using these approaches and others, we hope that significant progress can be made in treating this rare disease.Finally, the editors wish to thank all who contributed to this important series. It is our sincere hope that this special series will help to educate and inspire the development of innovative treatment approaches in these rare diseases that will impact patient outcomes.
Source: Frontiers in Oncology
Institutions: University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, Leipzig University, The Ohio State University, Thomas Jefferson University, Sidney Kimmel Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,950
OpenAlex ID: W4294868288